Skip to main
BMEA
BMEA logo

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 29%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion Inc. is advancing its clinical stage drug development, particularly with icovamenib, a selective covalent inhibitor of menin, which demonstrates significant benefits, including improved glycemic and body weight control, suggesting potential for enhanced efficacy in treating type 1 and type 2 diabetes and obesity. The company's proprietary FUSION System discovery platform further supports the development of its pipeline, including the investigational small-molecule GLP-1 receptor agonist, BMF-650, which could provide additional therapeutic options in the diabetes and obesity sectors. Significant improvements in clinical outcomes, such as a 1.0% mean reduction in HbA1c and enhanced glucose metabolism in combination with GLP-1-based therapies, bolster a positive outlook for Biomea Fusion's future growth and innovation in the metabolic disease treatment landscape.

Bears say

The analysis indicates a negative outlook on Biomea Fusion's stock, primarily due to the risks associated with clinical trials for its lead drug candidate, icovamenib, and ongoing financing challenges that could hinder drug development. Concerns have been raised regarding the company's ability to secure sufficient funding without resorting to dilutive capital raises, which could negatively impact shareholder value. Additionally, the current valuation adjustment to $16.00 reflects a conservative approach influenced by potential setbacks in clinical study outcomes and the overall uncertainty in the market for type 1 diabetes treatments.

BMEA has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 29% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Buy based on their latest research and market trends.

According to 14 analysts, BMEA has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.